1月15日，据CDE官网消息，鞍石药业（宁波）有限责任公司联合申请药品“PLB1004胶囊”，获得临床试验默示许可，受理号CXHL2401225。
公示信息显示，药品“PLB1004胶囊”适应症：PLB1004胶囊联合ANS014004片治疗经EGFR-TKI治疗失败后伴MET扩增或c-Met过表达的局部晚期或转移性非小细胞肺癌。
鞍石药业（宁波）有限责任公司，成立于2024年，位于宁波市，是一家以从事医药制造业为主的企业。企业注册资本500万人民币。
通过天眼查大数据分析，鞍石药业（宁波）有限责任公司。
主要股东信息显示，鞍石药业（宁波）有限责任公司由北京鞍石生物科技股份有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.